ArticleAmerican journal of cardiovascular disease2012
Autoimmune diseases and venous thromboembolism: a review of the literature.
Article in American journal of cardiovascular disease, 2012. The graph could read no effect estimate from its abstract, so it casts no vote on the map. It is linked to trial NCT06169865 (Prevalence of Peripheral Vascular Diseases and Presentation in Patients With Autoimmune Diseases), which is not on this map. Cited by 78 papers, 3 of them syntheses that pooled it.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Prevalence of Peripheral Vascular Diseases and Presentation in Patients With Autoimmune Diseases
Who cites it
78 citing papers in PubMed, 3 syntheses or guidelines pooled it, 118 citations in OpenAlex.
- The association between ankylosing spondylitis and the risk of venous thromboembolism: a meta-analysis.Frontiers in immunology · 2025Pooled it
- Association between systemic sclerosis and venous thromboembolism, pulmonary embolism, and deep vein thrombosis: a meta-analysis.Zeitschrift fur Rheumatologie · 2024Pooled it
- Idiopathic inflammatory myopathy and the risk of venous thromboembolism: a meta-analysis.Rheumatology international · 2017Pooled it
- Transcriptomic analysis identifies immune-related clusters and PPP2R1A as a candidate gene associated with venous thromboembolism recurrence.Archives of pharmacal research · 2026Article
- Association Between Charlson Comorbidity Index and Pressure Injury Stage: A Retrospective Cohort Study.International wound journal · 2026Article
- Thrombosis in Neuromuscular Medicine: Current Evidence, Unmet Needs, and Future Directions.Journal of clinical medicine · 2026Review
- Risk of Peripheral Artery Disease and Venous Thromboembolism in Patients with Neuromyelitis Optic Spectrum Disorder: A Nationwide Population-Based Cohort Study.International journal of medical sciences · 2026Article
- Evaluating the association between intravenous immunoglobulin and thromboembolic events in patients with autoimmune diseases: a retrospective real-world study.Frontiers in pharmacology · 2026Article
- Anti-OJ Antibody-positive Antisynthetase Myopathy Diagnosed after Pulmonary Embolization.Internal medicine (Tokyo, Japan) · 2025Article
- Review
- Exploring the Emerging Association Between Immune Checkpoint Inhibitors and Thrombosis.Journal of clinical medicine · 2025Review
- Aortic valve thrombosis in nephrotic syndrome: a case report.Journal of nephrology · 2025Article
- Early Change in C-Reactive Protein and Venous Thromboembolism in Patients Treated With Immune Checkpoint Inhibitors.JACC. CardioOncology · 2024Article
- Targeted anti-cancer agents and risk of venous thromboembolism.Haematologica · 2024Review
- Multimorbidity, comorbidity, frailty, and venous thromboembolism.Haematologica · 2024Review
- Resistance to tPA-induced fibrinolysis and activation of coagulation is present in autoimmune bullous diseases of the skin.Journal of thrombosis and haemostasis : JTH · 2024Article
- From Pulmonary Embolism to Chronic Thromboembolic Pulmonary Hypertension: A Pathophysiological Approach.Reviews in cardiovascular medicine · 2024Review
- Pulmonary Embolism in a Patient with Rheumatoid Arthritis on Etanercept Therapy.Journal of community hospital internal medicine perspectives · 2024Article
- Development and external validation of a prediction model for venous thromboembolism in systemic lupus erythematosus.RMD open · 2023Article
- Venous Thromboembolism After COVID-19 Infection Among People With and Without Immune-Mediated Inflammatory Diseases.JAMA network open · 2023Article
18 more citing papers are in PubMed but not listed here.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
4 authors at 1 institution in 1 country.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Venous thromboembolism (VTE) is major health problem and is sometimes complicated by lethal pulmonary embolism (PE). Disturbances of the coagulation and anticoagulation systems are important risk factors for VTE. Comparative studies suggest that coagulation and innate immunity have a shared evolutionary origin. It is therefore unsurprising that the immune and coagulation systems are linked, with many molecular components being important for both systems. Systemic inflammation modulates thrombotic responses by suppressing fibrinolysis, upregulating procoagulant, and downregulating anticoagulants, and autoimmune disorders such as systemic lupus erythematosus (SLE), inflammatory bowel disease (IBD), and Behçet's syndrome have been linked to an increased risk of VTE. Recent reports have further shown that a majority of autoimmune and immune-mediated disorders are linked to an increased risk of venous thrombosis, PE, or VTE. For instance, a Swedish nationwide study found that the risk of PE was increased in the first year after hospitalization for 33 different autoimmune disorders. Especially high risks were noted for several autoimmune diseases such as immune thrombocytopenic purpura, polyarteritis nodosa, polymyositis/dermatomyositis, ulcerative colitis, and SLE. Another study from England, also based on hospitalization data, found that immune-mediated disorders were associated with an increased risk of VTE compared with other medical causes of hospitalization. Multiple mechanisms may operate and disease-specific factors, such as cardiolipin antibodies, have been identified. However, inflammation by itself appears to change the hemostatic balance in a thrombogenic direction. Recent epidemiological studies, together with previous experimental and clinical studies, indicate that autoimmune disorders should not only be viewed as inflammatory disorders, but also hypercoagulable disorders. Research to identify thrombotic risk factors, elucidate the mechanisms involved, and investigate prophylactic regiments is needed. The present review describes the epidemiological, clinical, and experimental evidence for the connection between VTE and autoimmune and immune-mediated disorders.
Indexed as
Identifiers
22937487PMC3427982W1541710579What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.